ATE539078T1 - Isoxazolderivate enthaltende pharmazeutische zusammensetzung zur prävention und behandlung von restenose - Google Patents

Isoxazolderivate enthaltende pharmazeutische zusammensetzung zur prävention und behandlung von restenose

Info

Publication number
ATE539078T1
ATE539078T1 AT08778486T AT08778486T ATE539078T1 AT E539078 T1 ATE539078 T1 AT E539078T1 AT 08778486 T AT08778486 T AT 08778486T AT 08778486 T AT08778486 T AT 08778486T AT E539078 T1 ATE539078 T1 AT E539078T1
Authority
AT
Austria
Prior art keywords
pharmaceutical composition
prevention
treatment
isoxazole derivatives
restenoses
Prior art date
Application number
AT08778486T
Other languages
English (en)
Inventor
Sun Gwan Hwang
Sang Rak Choi
Jeong Woo Cho
Sung Jin Bae
Tae Sung Koo
So Young Lee
Kyung Chul Cho
Hyeon Cheol Gwon
Original Assignee
Sk Holdings Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Holdings Co Ltd filed Critical Sk Holdings Co Ltd
Application granted granted Critical
Publication of ATE539078T1 publication Critical patent/ATE539078T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT08778486T 2007-06-29 2008-06-30 Isoxazolderivate enthaltende pharmazeutische zusammensetzung zur prävention und behandlung von restenose ATE539078T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20070065481 2007-06-29
PCT/KR2008/003821 WO2009005269A2 (en) 2007-06-29 2008-06-30 Pharmaceutical composition for preventintion and treatment of restenosis comprising isoxazole derivatives
KR1020080062297A KR101464302B1 (ko) 2007-06-29 2008-06-30 아이속사졸 유도체를 포함하는 혈관재협착 예방 및 치료용약학 조성물

Publications (1)

Publication Number Publication Date
ATE539078T1 true ATE539078T1 (de) 2012-01-15

Family

ID=40486904

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08778486T ATE539078T1 (de) 2007-06-29 2008-06-30 Isoxazolderivate enthaltende pharmazeutische zusammensetzung zur prävention und behandlung von restenose

Country Status (8)

Country Link
US (1) US8518978B2 (de)
EP (1) EP2170876B1 (de)
JP (1) JP5311075B2 (de)
KR (1) KR101464302B1 (de)
CN (1) CN101778845B (de)
AT (1) ATE539078T1 (de)
ES (1) ES2379746T3 (de)
WO (1) WO2009005269A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101778845B (zh) 2007-06-29 2014-06-25 爱思开生物制药株式会社 用于预防和治疗再狭窄的包含异噁唑衍生物的药物组合物
EP2438052A1 (de) 2009-06-05 2012-04-11 Oslo University Hospital HF Azolderivate als hemmer des wtn-signalweges
CN103429583A (zh) 2010-12-08 2013-12-04 奥斯陆大学医院公司 作为wnt信号通路抑制剂的三唑衍生物
WO2015073274A1 (en) * 2013-11-13 2015-05-21 Albert Einstein College Of Medicine Of Yeshiva University Wnt/beta-catenin inhibitor-eluting endovascular stent
CA2942386A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
AU2015229117A1 (en) 2014-03-13 2016-09-29 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity
EP3157917B1 (de) 2014-06-19 2020-03-18 Proteostasis Therapeutics, Inc. Verbindungen, zusammensetzungen und verfahren zur steigerung der cftr-aktivität
WO2016086092A1 (en) 2014-11-25 2016-06-02 The Penn State Research Foundation Chemical reprogramming of human glial cells into neurons for brain and spinal cord repair
WO2016105477A1 (en) 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc Derivatives of 5-phenyl- or 5-heteroarylthiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis
WO2016105468A1 (en) * 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc. Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis
US10738011B2 (en) 2014-12-23 2020-08-11 Proteostasis Therapeutics, Inc. Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
MA41253A (fr) 2014-12-23 2017-10-31 Proteostasis Therapeutics Inc Composés, compositions et procédés pour augmenter l'activité du cftr
US10548878B2 (en) 2015-07-24 2020-02-04 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods of increasing CFTR activity
SG11201802798WA (en) 2015-10-06 2018-05-30 Proteostasis Therapeutics Inc Compounds, compositions, and methods for modulating cftr
CN107056754B (zh) * 2015-12-07 2020-12-04 苏州信诺维医药科技有限公司 内嵌脲类结构的wnt通路抑制剂
WO2017177124A1 (en) 2016-04-07 2017-10-12 Proteostasis Therapeutics, Inc. Silicone atoms containing ivacaftor analogues
ES2954658T3 (es) 2016-06-21 2023-11-23 Proteostasis Therapeutics Inc Compuestos, composiciones y procedimientos para aumentar la actividad de CFTR
US20220409590A1 (en) * 2019-11-25 2022-12-29 The Penn State Research Foundation Chemotherapy for glioma through neuronal conversion
KR20240008354A (ko) * 2021-05-18 2024-01-18 유니버시티 오브 써던 캘리포니아 인간 과립구-대식세포 전구체의 확장 방법 및 그의 적용
CN116554461B (zh) * 2022-01-29 2026-03-31 华东理工大学 聚合物在促进介入/植入材料内皮化中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ530782A (en) 2001-08-06 2005-11-25 Pharmacia Italia S Aminoisoxazole derivatives active as kinase inhibitors
KR101394245B1 (ko) 2005-12-30 2014-05-14 에스케이바이오팜 주식회사 아이속사졸 유도체 및 이의 용도
WO2008070739A1 (en) * 2006-12-06 2008-06-12 Cytokinetics, Inc. Ksp activators
CN101778845B (zh) 2007-06-29 2014-06-25 爱思开生物制药株式会社 用于预防和治疗再狭窄的包含异噁唑衍生物的药物组合物

Also Published As

Publication number Publication date
WO2009005269A2 (en) 2009-01-08
US20110028506A1 (en) 2011-02-03
ES2379746T3 (es) 2012-05-03
JP2010532344A (ja) 2010-10-07
EP2170876A2 (de) 2010-04-07
EP2170876A4 (de) 2010-10-27
JP5311075B2 (ja) 2013-10-09
US8518978B2 (en) 2013-08-27
CN101778845B (zh) 2014-06-25
KR101464302B1 (ko) 2014-11-26
KR20090004612A (ko) 2009-01-12
WO2009005269A3 (en) 2009-02-26
CN101778845A (zh) 2010-07-14
EP2170876B1 (de) 2011-12-28

Similar Documents

Publication Publication Date Title
WO2009005269A3 (en) Pharmaceutical composition for preventintion and treatment of restenosis comprising isoxazole derivatives
ATE376828T1 (de) Verwendung von rotigotin zur behandlung und prävention des parkinson-plus-syndroms
EA200800798A1 (ru) Фармацевтические композиции, предназначенные для лечения нарушений внутреннего уха
TNSN08070A1 (en) Benzoquinazoline derivatives and their use in treating bone disorders
MX2013013809A (es) Dispositivos expandibles con revestimiento de una composicion de paclitaxel.
MX2010002353A (es) Amidas heterociclicas utiles para tratamiento de cancer y psoriais.
ATE534377T1 (de) Verfahren und zusammensetzungen zur behandlung von hämatologischen erkrankungen
ATE511392T1 (de) Verzögert freigesetzte orale dosierungsformen eines prodrugs von r-baclofen und behandlungsverfahren damit
ATE502633T1 (de) Cyclosporins zur behandlung und vorbeugung von augenerkrankungen
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
BR0313747A (pt) Inibidores de transcriptase reversa de não-nucleosìdeo
ATE456369T1 (de) Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
NO20083758L (no) Nye terapautiske kombinasjoner for behandling av depresjon
DE602008004540D1 (de) 2-oxo-2-(2-phenyl-5,6,7,8-tetrahydroindolizin-3-yl)acetamidderivate und verwandte verbindungen als antipilzmittel
TW200806299A (en) Treatment of pain
SG178975A1 (en) Indenone derivative and pharmaceutical composition comprising same
EA201071006A1 (ru) Набор, композиция, продукт или лекарственное средство для лечения нарушения познавательной способности
EP1921077A4 (de) Mittel zur behandlung und/oder prävention von schlafstörungen
DE502005008058D1 (de) Gesättigte und ungesättigte 3-pyridyl-benzocycloalkylmethyl-amine zur behandlung von schmerzen, depressionen und angstzuständen
DE602007011975D1 (de) Thiadiazolderivate zur behandlung neurodegenerativer krankheiten
ATE447948T1 (de) Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von schmerzen
MY196807A (en) Chromane, isochromane and dihydroisobenzofuran derivatives as mglur2-negative allosteric modulators, compositions, and their use
MX2013013808A (es) Dispositivos expandibles con revestimiento de una composicion de rapamicina.
ATE541567T1 (de) Pharmazeutische zusammensetzung zur prävention und behandlung von metabolischen knochenerkrankungen mit alpha-arylmethoxyacrylat- derivaten
JP2008513426A5 (de)